Hemostemix Closes CDN$280,594 Private Placement

Rhea-AI Summary

Hemostemix (OTCQB: HMTXF) announced a conditionally approved non-brokered private placement of CDN$280,594.

The Offering consists of 2,244,752 common shares at CDN$0.125 per share, subject to final TSX Venture Exchange approval. The investor is arm's length to the company and not a related party.

Proceeds will be used for general working capital to support ongoing operations and business development. All securities will be subject to a four-month hold period under Canadian securities laws and any additional applicable restrictions.

Positive

• CDN$280,594 raised to support working capital
• Issuance of 2,244,752 shares provides immediate funding for operations

Negative

• Issuance of 2,244,752 shares will dilute existing shareholders
• Offering is subject to final TSXV approval, not yet closed

Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces the TSX Venture Exchange ("TSXV") conditionally approved the Company's previously disclosed non-brokered private placement (the "Offering") in the amount of CDN $280,594. The Offering consisted of the issuance of 2,244,752 Common Shares at a price of CDN $0.125 per Common Share. Subject to final TSXV approval, the Company will issue 2,244,752 Common Shares.

As per TSXV Policy 4.1, the investor is arm's length to the Company and is not a Related Party to the Company at the time of disclosure.

The use of proceeds will be allocated to general working capital purposes, supporting the Company's continuing operational expenses and business development activities.

The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed.

All securities issued in connection with the Offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

For further information, please contact:

Thomas Smeenk, President, CEO & Co-Founder:
EM: tsmeenk@hemostemix.com / PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the financing of the Company related to the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275088

FAQ

How much did Hemostemix (HMTXF) raise in the November 18, 2025 private placement?

Hemostemix conditionally raised CDN$280,594 through the private placement.

How many shares did Hemostemix (HMTXF) issue in the private placement and at what price?

The Offering consists of 2,244,752 common shares issued at CDN$0.125 per share.

What will Hemostemix (HMTXF) use the private placement proceeds for?

Proceeds are allocated to general working capital to support operational expenses and business development.

Is the Hemostemix (HMTXF) private placement final and are there resale restrictions?

The Offering is subject to final TSXV approval and all securities are under a four-month hold period from closing under Canadian law.

Was the investor in Hemostemix's (HMTXF) offering a related party?

As disclosed, the investor is arm's length and was not a related party at the time of disclosure.